This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Advanced Malignant Solid Neoplasm
and you are
over 18
years old
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This phase I trial studies the side effects and best dose of EphA2 siRNA in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or have come back after a period of improvement (recurrent). EphA2-targeting DOPC-encapsulated siRNA may slow the growth of tumor cells by shutting down the activity of a gene that causes tumor growth.

Provided treatments

  • Drug: EphA2-targeting DOPC-encapsulated siRNA
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01591356. The sponsor of the trial is M.D. Anderson Cancer Center and it is looking for 75 volunteers for the current phase.
Official trial title:
EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery: A Phase I Clinical Trial